Form 4 Filing for Camp4 Therapeutics Corp

This filing details a transaction by Gold Kelly, Chief Financial Officer of Camp4 Therapeutics Corp. On August 31, 2026, Kelly acquired 10,000 shares of Common Stock in an open market purchase at a weighted average price of $3.96 per share, with prices ranging from $3.88 to $4.00. This acquisition brings the total shares owned following the transaction to 10,000. An additional 76,467 shares are held indirectly, co-owned with her spouse, David Gold, over which she disclaims investment control. The filing also notes 2,039 shares previously acquired under the company's Employee Stock Purchase Plan. The transaction is reported on Form 4.